home / stock / smfr / smfr news


SMFR News and Press, Sema4 Holdings Corp. From 11/04/22

Stock Information

Company Name: Sema4 Holdings Corp.
Stock Symbol: SMFR
Market: NASDAQ

Menu

SMFR SMFR Quote SMFR Short SMFR News SMFR Articles SMFR Message Board
Get SMFR Alerts

News, Short Squeeze, Breakout and More Instantly...

SMFR - Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022

STAMFORD, Conn., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced it will release financial results for the third quarter of 2022 before the market opens on Monday, November 14, 2022. On the same day, Katherine Stueland , Chief Execu...

SMFR - Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies

STAMFORD, Conn., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, supports the new National Society of Genetic Counselors guidelines recommending exome sequencing as a first-tier test, to be prioritized over multi-gene panels for all individuals wit...

SMFR - Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns

-- Abnormal findings reported in 63% of infants in study, change in health management recommended in 88% of cases -- -- Sema4|GeneDx contributes to latest data in the SeqFirst study being presented at the American Society of Human Genetics Annual Meeting -- STAMFORD, Conn., Oc...

SMFR - Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels

STAMFORD, Conn., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, has collaborated on research debunking a commonly held belief that exome and genome sequencing deliver more inconclusive results than multi-gene panels. The study demonstrates that using ...

SMFR - Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders

Research from 19,000 patients with Autism Spectrum Disorders found approximately 90% had prior negative tests, likely contributing to a longer time to diagnosis Data will be presented at the Child Neurology Society (CNS) Annual Meeting on October 13, 2022 STAMFORD, Conn., ...

SMFR - Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study

STAMFORD, Conn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced it is a partner in the recently launched GUARDIAN study (Genomic Uniform-screening Against Rare Diseases In All Newborns), a collaboration among premier non-profit, academ...

SMFR - DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2022 in Sema4 Holdings Corp. Lawsuit - SMRF

New York, New York--(Newsfile Corp. - September 15, 2022) - Levi & Korsinsky, LLP notifies investors in Sema4 Holdings, Corp. ("Sema4 Holdings Corp." or the "Company") (NASDAQ: SMFR) of a class action securities lawsuit. The lawsuit on behalf of Sema4 Holdings Corp. investors has been c...

SMFR - DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2022 in Sema4 Holdings Corp. Lawsuit - SMFR

New York, New York--(Newsfile Corp. - September 14, 2022) - Levi & Korsinsky, LLP notifies investors in Sema4 Holdings, Corp. ("Sema4 Holdings Corp." or the "Company") (NASDAQ: SMFR) of a class action securities lawsuit. The lawsuit on behalf of Sema4 Holdings Corp. investors has been c...

SMFR - Sema4 Deadline Alert

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sema4 To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - September 9, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, ...

SMFR - Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sema4 To Contact Him Directly To Discuss Their Options

NEW YORK, NY / ACCESSWIRE / September 7, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sema4 Holdings Corp. ("Sema4" or the "Company") (NASDAQ:SMFR) and reminds investors of the November 7, 2022 deadline to seek the role of...

Previous 10 Next 10